Alpelisib (BYL719)

目录号:S2814 中文名称:阿培利司

仅限科研使用

Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂,在无细胞试验中IC50为 5 nM,对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

Alpelisib (BYL719) Chemical Structure

CAS: 1217486-61-7

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 876.4 现货
RMB 728.96 现货
RMB 1204.67 现货
RMB 5463.3 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Alpelisib (BYL719)发表文献153篇:

产品安全说明书

PI3K抑制剂选择性比较

相关PI3K产品

生物活性

产品描述 Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂,在无细胞试验中IC50为 5 nM,对PI3Kβ/γ/δ具有极弱的作用。Phase 2。
靶点
PI3Kα [1]
(Cell-free assay)
5 nM
体外研究

BYL719抑制含有PIK3CA突变体的乳腺癌细胞系的增殖,与PI3K/Akt通路各种下游信号组分的抑制相关。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Detroit562 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSwMlEuOTByIN88US=> NGnYUnI4OiCq MYPJR|UxRTFwMUCg{txO Mli4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUC1OFkoRjJ3NUWwOVQ6RC:jPh?=
SNU-1076 NIS5OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6wMlEuOTByIN88US=> MYe3NkBp M2HRNWlEPTB;Nj64NkDPxE1? NHHHZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
SNU-1066 NV[1O41oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrnNE4yNTFyMDFOwG0> MVG3NkBp MXvJR|UxRTFwMUOg{txO MlGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUC1OFkoRjJ3NUWwOVQ6RC:jPh?=
FaDu M3fn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M361XFAvOS1zMECg{txO MoniO|IhcA>? NUDnfm5RUUN3ME2xPU43PiEQvF2= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3MEW0PUc,OjV3NUC1OFk9N2F-
SNU1041 NGn2VlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHWNE4yNTFyMDFOwG0> M3rMPVczKGh? NH3N[41KSzVyPUKwMlY2KM7:TR?= NE\RSVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
SCC25 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjSOnllOC5zLUGwNEDPxE1? M4\r[lczKGh? M1LmPWlEPTB;NEmuN|Ah|ryP MlzwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUC1OFkoRjJ3NUWwOVQ6RC:jPh?=
BON-1 Mn3LSpVv[3Srb36gRZN{[Xl? MXGxM|ExKM7:TR?= MYO0JIg> NInkeGVqdmirYnn0d{BRUTONIDjBT3QhW2W{M{C4LUBidmRibWTPVmMyNzJiYXP0bZZqfGmncx?= NYXrcYMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
QGP-1 NVHGOWdQTnWwY4Tpc44hSXO|YYm= Mkf6NU8yOCEQvF2= MXm0JIg> MlnVbY5pcWKrdIOgVGk{UyBqQVvUJHNmejNyODmgZY5lKG2WT2LDNU8zKGGldHn2bZRq\XN? M33veVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK2NlkzLz5{NUCyOlI6OjxxYU6=
MG-63 M{nNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XieGlEPTB;NjFOwG3wxIxiSVO5NF0zPCEQvF2= M2PvNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[xO|kxLz5{NEm2NVc6ODxxYU6=
HOS NFfVe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF3IN88Ug+9lCCLQ{mwQVQzKM7:TR?= NYLKeVFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
MOS-J NHy5UmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXjOIpNUUN3ME2xNEDPxE4xvJygTWM6OD1|NjFOwG0> NX\UO5pwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
POS-1 MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3OTWM2OD16IN88Ug+9lCCLQ{mwQVM3KM7:TR?= NUDZc4RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
92.1 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K4VVUxOC1{MECwJI5O NVHTXGJMPSCm MWDpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> MljLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NkO1OFAoRjJ2NU[zOVQxRC:jPh?=
Mel270 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj2dI42ODBvMkCwNEBvVQ>? MXW1JIQ> NX3CSYN[cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1? NX3idHcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlM2PDBpPkK0OVY{PTRyPD;hQi=>
Omm1.3 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYe1NFAuOjByMDDuUS=> NYizRWhVPSCm MWHpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> NF3hdYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N|U1OCd-MkS1OlM2PDB:L3G+
Omm1 NHXTWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTpTmI2ODBvMkCwNEBvVQ>? NVHSSZI6PSCm M3nmRolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO NHLk[3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N|U1OCd-MkS1OlM2PDB:L3G+
C918 M2\MPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfXbZVpPTByLUKwNFAhdk1? MmLQOUBl MWLpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4M{W0NEc,OjR3NkO1OFA9N2F-
Mel290 M4\UO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7NS282ODBvMkCwNEBvVQ>? M3PzWFUh\A>? NXHyXoZzcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1? M3vMXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[zOVQxLz5{NEW2N|U1ODxxYU6=
OPM2 NUXTT4tjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rpWlAvPS1{LkWg{txO NVvuRpcxPDhiaB?= NVewW|NDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
OPM1 NYnvXFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm3elJHOC53LUKuOUDPxE1? NFn2fZI1QCCq M3\5SYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
U266 M1jGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDnNWMxNjVvMj61JO69VQ>? NY\DcW57PDhiaB?= NH;WWm1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX3i[oJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFUyOjFpPkK0OFA2OTJzPD;hQi=>
MM1R MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH65fpoxNjVvMj61JO69VQ>? NV;zRXc6PDhiaB?= NWDoZm97cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml6yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
MM1S NXPoOoxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP3NE42NTJwNTFOwG0> NHy0emY1QCCq MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGq3cpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVEzOSd-MkS0NFUyOjF:L3G+
H929 MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWwMlUuOi53IN88US=> NF;zelg1QCCq M1yyPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVfY[WliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFUyOjFpPkK0OFA2OTJzPD;hQi=>
RPMI MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWwMlUuOi53IN88US=> MmHBOFghcA>? NWC5N2dCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MljrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
SKBR3 NHzKZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfaVIc{OyEQvF2= NGj2OZE2KGR? MUDpcohq[mm2czCzOg+9jSClZXzsJIdzd3e2aB?= Mm\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
MDA453 NYnn[m5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF61O3g{OyEQvF2= M3voUVUh\A>? NH:4cXRqdmirYnn0d{A{QO,:hTDj[YxtKGe{b4f0bC=> M4H6T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
EFM192A NGXD[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7aN|Mh|ryP NIrHfYg2KGR? MUfpcohq[mm2czCyO-+9jSClZXzsJIdzd3e2aB?= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
AU565 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS3SWd7OzNizszN NUmwT5J[PSCm NWXVOppJcW6qaXLpeJMhOjcxvJWgZ4VtdCCpcn;3eIg> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
MDA361 NX7xc|ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfTN|Mh|ryP M4HiT|Uh\A>? NFvxSGtqdmirYnn0d{A1PO,:hTDj[YxtKGe{b4f0bC=> NVLGeFNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
BT474 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjRN|Mh|ryP MV61JIQ> MV\pcohq[mm2czCxOw+9jSClZXzsJIdzd3e2aB?= NEXsVIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
HCC202 M1r1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;BUpc{OyEQvF2= MnvBOUBl M2jGeYlvcGmkaYTzJFIx97zHIHPlcIwh\3Kxd4To MlHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
KPL4 M3nLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjqZmU{OyEQvF2= NFvDSm02KGR? MWrpcohq[mm2czC1PQ+9jSClZXzsJIdzd3e2aB?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
NCL-N87 NUTIclRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2xN|Mh|ryP NHL0epk2KGR? MoexbY5pcWKrdIOgN|HwxIViY3XscEBoem:5dHi= M{TsT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
UACC812 M{DqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSzN{DPxE1? MY[1JIQ> NXGwdod4cW6qaXLpeJMhOjgxvJWgZ4VtdCCpcn;3eIg> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
HCC2218 M{m1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXBfpNoOzNizszN MkC1OUBl NFuwT|NqdmirYnn0d{AyPe,:hTDj[YxtKGe{b4f0bC=> NGi0O4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
HCC1569 M{m3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjBN|Mh|ryP MkXGOUBl MYfpcohq[mm2czC189yGKGOnbHyg[5Jwf3Sq M3PpXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
OE19 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSzN{DPxE1? MUG1JIQ> M4LteYlvcGmkaYTzJFI{97zHIHPlcIwh\3Kxd4To M3TXXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
OE33 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXuN|Mh|ryP NXTxZXVoPSCm NYTIWVFwcW6qaXLpeJMhOjQxvJWgZ4VtdCCpcn;3eIg> MnjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
JIMT1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnDN|Mh|ryP MlX4OUBl MnO1bY5pcWKrdIOgPg+9jSClZXzsJIdzd3e2aB?= M2rRblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
HCC1954 M1nweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vFRVM{KM7:TR?= NHfOOFk2KGR? MXnpcohq[mm2czCyPg+9jSClZXzsJIdzd3e2aB?= M33pVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
NUGC4 MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\SN|Mh|ryP NUXLeGtzPSCm MlPtbY5pcWKrdIOgNVTwxIViY3XscEBoem:5dHi= NFnTSWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
ZR-75-30 NUfSSZh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWzN{DPxE1? NWCyN|lmPSCm MYLpcohq[mm2czCtNVXwxIViY3XscEBoem:5dHi= Ml\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
Rat1 M1ezOnAyOTCjbIDoZUBqdmirYnn0bY9vKGG|c3H5 NFTDNJZKSzVyIE2gNE4xPzRizszN NYTKWY5rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlQyQDlpPkK2NVY1OTh7PD;hQi=>
Rat1 MYDQTVNM[WyyaHGgbY5pcWKrdHnvckBie3OjeR?= NFjvPY1KSzVyIE2gNE4xPzRizszN MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[1NFQoRjJ4MkC2OVA1RC:jPh?=
Rat1 MUHQNVEx[WyyaHGgbY5pcWKrdHnvckBie3OjeR?= MkLKTWM2OCB;IECuNFc1KM7:TR?= MnOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mk[wN|QoRjJ|N{K2NFM1RC:jPh?=
Rat1 M1X2cXAyOTCmZXz0ZUBqdmirYnn0bY9vKGG|c3H5 MmT5TWM2OCB;IEGuNkDPxE1? NVzxNppxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlQyQDlpPkK2NVY1OTh7PD;hQi=>
Rat1 NYjwN3puWEl|S3fhcY1iKGmwaHnibZRqd25iYYPzZZk> MXrJR|UxKD1iMT6yJO69VQ>? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJyNkWwOEc,OjZ{ME[1NFQ9N2F-
Rat1 M2TY[HAyOTCmZXz0ZUBqdmirYnn0bY9vKGG|c3H5 NVf6OGNMUUN3MDC9JFEvOiEQvF2= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{NkCzOEc,OjN5Mk[wN|Q9N2F-
Rat1 M2DvSnAyOTCkZYThJIlvcGmkaYTpc44h[XO|YYm= MXzJR|UxKD1iMj6yJO69VQ>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4NEG4PUc,OjZzNkSxPFk9N2F-
Rat1 MWDQTVNM[mW2YTDpcohq[mm2aX;uJIF{e2G7 M1vyRmlEPTBiPTCyMlIh|ryP M4T0OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkC2OVA1Lz5{NkKwOlUxPDxxYU6=
Rat1 M3fKfnAyOTCjbIDoZUBqdmirYnn0bY9vKGG|c3H5 NEDvTHNKSzVyIE2gNk4zKM7:TR?= NYD5[IVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NlYxOzRpPkKzO|I3ODN2PD;hQi=>
Assay
Methods Test Index PMID
Western blot p-AKT(S473) / p-AKT(T308) p100β / p110α / p85 / p-ERBB3(Y1289) p-HER2 / IGF-1R pS6 (Ser235-236) PIM1 / PIM2 / PIM3 / p-PRAS40 / p-RPS6 / p-BAD 25544637 27048245 27604488
Growth inhibition assay Cell viability 27602501
Immunofluorescence LC3 26637440
体内研究 BYL719(>270 mg/d)在PIK3CA突变体异种移植啮齿动物模型中表现出统计学显著的剂量依赖性抗肿瘤效能。BYL719具有低清除率,半衰期为8.5小时,并且它的作用在30mg/d 和450mg/d之间剂量成比例的增加,在人的Cmax 和AUC中显示出低的个体差异。BYL719(270mg/d)首次表现出临床疗效的迹象,包括在ER+乳腺癌患者中证实的部分响应,以及17个患者中8个实现了显著的PET响应(PMR)和/或肿瘤治愈。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O

4.4 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 441.47
化学式

C19H22F3N5O2S

CAS号 1217486-61-7
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05230810 Not yet recruiting Drug: Alpelisib|Drug: Tucatinib|Drug: Fulvestrant HER2-positive Metastatic Breast Cancer Criterium Inc.|Novartis|Seagen Inc. June 30 2022 Phase 1|Phase 2
NCT05143229 Recruiting Drug: Alpelisib|Drug: Sacituzumab govitecan Breast Cancer University of Kansas Medical Center|Novartis Pharmaceuticals|Gilead Sciences March 28 2022 Phase 1
NCT05195892 Recruiting Drug: Treatment A|Drug: Treatment B|Drug: Treatment C Healthy Volunteers Novartis Pharmaceuticals|Novartis February 3 2022 Phase 1
NCT04980833 Recruiting Drug: Alpelisib PIK3CA-related Overgrowth Spectrum (PROS) Novartis Pharmaceuticals|Novartis January 27 2022 Phase 2
NCT04997902 Recruiting Drug: Tipifarnib|Drug: Alpelisib HNSCC Kura Oncology Inc. December 7 2021 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy Alpelisib (BYL719) | Alpelisib (BYL719) supplier | purchase Alpelisib (BYL719) | Alpelisib (BYL719) cost | Alpelisib (BYL719) manufacturer | order Alpelisib (BYL719) | Alpelisib (BYL719) distributor